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Veno-occlusive disease (VOD) of the liver is a well-described and signiﬁcant complication of hematopoietic
stem cell transplantation (HSCT), with limited successful therapeutic options in severe cases. Prompt diag-
nosis and initiation of treatment is crucial to restrict the extent of disease. However, a subset of patients may
not meet all current diagnostic criteria at presentation, and waiting for these to be met may delay therapy. We
retrospectively reviewed 794 HSCT patients treated at our institution between 2003 and 2013, identifying 17
(2.1%) who developed VOD. Of these, 5 (29%) were noted to have an absence of elevated bilirubin at the time
of VOD diagnosis and reversal of portal venous ﬂow on ultrasound. Median total and conjugated bilirubin at
VOD diagnosis were 1.0 and 0.2 mg/dL, respectively. All 5 patients were subsequently diagnosed with mul-
tiorgan failure associated with VOD, including 1 with encephalopathy. Four were treated with intravenous
high-dose methylprednisolone (500 mg/m2 per dose every 12 hours for 6 doses). One patient received
deﬁbrotide therapy in addition to steroids and another supportive care alone. VOD resolved in 4 of 5 patients,
with median time to resolution of VOD, deﬁned as recovery of all organ function and normalization of bili-
rubin and portal venous ﬂow, of 8 days. Two patients died later from progressive primary disease and chronic
graft-versus-host disease, respectively. We conclude that a high index of suspicion for VOD should be
maintained in patients despite lack of bilirubin elevation in the presence of other diagnostic criteria such as
hepatomegaly, abdominal pain, ascites, or weight gain. Early ultrasound evaluation in these patients may lead
to more timely diagnosis and therapeutic interventions.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Veno-occlusive disease (VOD) is a life-threatening
complication of hematopoietic stem cell transplantation
(HSCT) classically characterized by hyperbilirubinemia,
painful hepatomegaly, rapid weight gain, and ascites [1].
VOD has been reported in up to 55% of patients after HSCT
with high-dose alkylator therapy [2]. Injury to sinusoidal
endothelial cells in zone 3 of the hepatic acinus most
commonly leads to this constellation of symptoms. Incidence
varies according to the type of transplant (autologous versus
allogeneic), stem cell source, and preparative regimen. The
diagnosis of VOD is made clinically based on either the Bal-
timore criteria of hyperbilirubinemia (total serum bilirubin
>2 mg/dL), tender hepatomegaly or right upper quadrant
pain, and weight gain more than 5% over baseline or ascites
or the Seattle criteria, which requires 2 of these parameters
to be met before day þ20 [2]. Clinically, VOD ranges from a
mild, reversible disease to a much more severe syndrome
with multiorgan failure (MOF) and high mortality,
approaching 100% by day þ100 post-HSCT [1]. Treatment
modalities are limited, especially for severe disease, making
early diagnosis and intervention key. In this report, we
describe our institutional experience with diagnosis, treat-
ment, and outcomes of moderate to severe VOD in thedgments on page 381.
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Based on our clinical observations that some patients develop a typical
constellation of VOD symptoms, including reversal ﬂow in the portal system
and multiorgan impairment, in the absence of high bilirubin, we performed
a retrospective review of HSCT patients treated at Cincinnati Children’s
Hospital Medical Center from January 1, 2003 until February 30, 2013 to
identify patients with a diagnosis of VOD without hyperbilirubinemia at the
time of disease presentation.
This research was performed with institutional review board approval.
All patients with a clinical diagnosis of VOD by either Seattle or Baltimore
criteria were identiﬁed, clinical records reviewed, and data abstracted. Data
included patient demographics, clinical and transplant-speciﬁc data,
radiologic and laboratory studies, therapeutic interventions, overall out-
comes, and related complications.
For the purpose of this study we further selected patients with a diag-
nosis of VOD deﬁned as the presence of at least 2 of the following symp-
toms: weight gain of at least 5% above pretransplant baseline, ascites, or
hepatomegaly increased above baseline, regardless of bilirubin. All these
patients had documented reversal of portal venous ﬂow evidenced by ul-
trasound. A diagnosis of severe VODwithMOFwas deﬁned by the additional
presence of respiratory and/or renal dysfunction. Pulmonary dysfunction
was diagnosed in patients requiring oxygen supplementation/ventilator
support secondary to ﬂuid overload or mechanical impingement from
abdominal distention and/or hepatic enlargement. Renal dysfunction was
diagnosed in patients requiring renal replacement therapy or with serum
creatinine at least 2 times higher than the pretransplant value.Therapy
High-dose steroid therapy, as previously described [3], consisted of
intravenous methylprednisolone 500 mg/m2 per dose every 12 hours for 6
doses. The subject receiving deﬁbrotide was enrolled in an institutional
review boardeapproved compassionate-use study.
Table 1
Patient and HSCT Characteristics
Diagnosis Gender Age (yr) Donor Match Prep GVHD Prophylaxis
1 AML Male 14.6 MUD 7/8 Cy/ATG CSA/Mtx
2 Pleuropulmonary blastoma Female 7 Auto Bu/Mel/thiotepa N/A
3 ALL Male 4.8 MUD 8/8 Cy/thiotepa TBI Siro/Tacro/Mtx
4 Neuroblastoma Male 2.8 Auto Carbo/VP16 Mel N/A
5 Neuroblastoma Male 3.4 Auto Bu/Mel N/A
GVHD indicates graft-versus-host disease; AML, acute myeloid leukemia; MUD, matched unrelated donor; Cy, cyclophosphamide; ATG, antithymocyte globulin;
CSA, cyclosporine; Mtx, methotrexate; Auto, autologous stem cell transplant; Bu, busulfan; Mel, melphalan; N/A, not applicable; ALL, acute lymphoblastic
leukemia; TBI, total body irradiation; Siro, sirolimus; Tacro, tacrolimus; Carbo, carboplatin; VP16, etoposide.
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Complete resolution of VOD was deﬁned as recovery of all organ func-
tion, return to baseline weight, and normalization of bilirubin and portal
venous ﬂow. Resolution of renal dysfunction was deﬁned as serum creati-
nine less than 1.5 times the pretransplant value and discontinuation of renal
replacement therapy. Resolution of pulmonary dysfunction was deﬁned as
cessation of ventilator support, oxygen usage, and documentation of oxygen
saturation more than 90% on room air for at least 24 hours.
Patient Monitoring
All HSCT patients had standard uniform monitoring, prophylactic, and
supportive care per institutional practice. Patients with suspected or diag-
nosed VOD had daily measurements of total and direct bilirubin, complete
blood count, ﬁbrinogen, prothrombin time, partial thromboplastin time,
blood urea nitrogen, and serum creatinine. Liver Doppler sonography to
evaluate for a reversal of blood ﬂow in the portal system was performed at
attending physician discretion. HSCT patients requiring intensive care unit
admissionwere cared for by both Bone Marrow Transplantation and Critical
Care teams.
RESULTS
Patient Characteristics
In a retrospective review of 794 HSCT patients consecu-
tively treated at our institution since 2003, we identiﬁed 17
individuals (2.1%) who developed severe VOD. Of these 17
individuals, 5 (29%) were noted to have an absence of
elevated bilirubin at the time of VOD diagnosis by Seattle
criteria, and these 5 patients are described in further anal-
ysis. All 5 patients also had reversal of portal venous ﬂow on
ultrasound at the time of VOD diagnosis.
Patient demographic and transplant characteristics are
shown in Table 1. Median patient age was 4.8 years (range,
2.8 to 14.6), and most patients (4/5) were male. Two patients
received allogeneic HSCT and 3 autologous. All administered
preparative regimens were myeloablative.Table 2
VOD Characteristics and Outcome
Patient Diagnosis Doppler
of Portal
System (d)
Bilirubin at Flow
Reversal
Total/Conjugated
(mg/dL)
Maximum Bilirub
Total/Conjugated
(mg/dL)
1 AML Reversal of
ﬂow (20)
1.9/1.2 8.5/7.4
2 Pleuropulmonary
blastoma
Reversal of
Flow (26)
1.0/0 4.8/3.4
3 ALL Reversal of
ﬂow (12)
.4/0 1.1/.7
4 Neuroblastoma Reversal of
ﬂow (11)
1.0/.2 1.3/.5
5 Neuroblastoma Reversal of
ﬂow (19)
1.5/.7 2.3/1.4
PD indicates progressive disease; HD, high dose.
* Respiratory and renal failure.
y Hepatic encephalopathy.VOD Characteristics and Outcomes
VOD was diagnosed by at least 2 of the following symp-
toms: weight gain of at least 5% above pretransplant base-
line, ascites, or hepatomegaly increased above baseline,
regardless of bilirubin in all 5 patients. Four patients
demonstrated sonographic evidence showing reversal of
portal venous ﬂow on or before day þ20 of transplantation.
One patient presented with late VOD conﬁrmed by ultra-
sound on day þ26 during an outpatient follow-up visit.
Median total and conjugated bilirubin at diagnosis were 1.0
and 0.2 mg/dL, respectively (normal range, .1 to 1.1 and 0 to
.3 mg/dL, respectively). All ﬁve patients hadMOF at diagnosis
of VOD with elevated coagulation markers, renal impair-
ment, and a respiratory support requirement with supple-
mental oxygen (Table 2). One patient had hepatic
encephalopathy requiring plasmapheresis and renal
replacement therapy for 2 days but eventually resolved both
neurologic symptoms and VOD. None of these patients
required mechanical ventilation for respiratory support.
Four patients were treated with intravenous high-dose
methylprednisolone (500 mg/m2 per dose every 12 hours
for 6 doses), and 1 patient also received deﬁbrotide therapy.
One patient received only supportive care, including ﬂuid
restriction and diuresis before the availability of deﬁbrotide
and before institutional adoption of high-dose steroid ther-
apy for VOD. VOD resolved in 4 of 5 patients after a median of
8 days (range, 6 to 69). The individual who did not resolve
VOD achieved normalization of portal venous ﬂow but had
persistent ascites and weight gain at the time of his death
due to progressive primary disease. An additional patient
later died from chronic graft-versus-host disease after reso-
lution of VOD.in MOF VOD Therapy
(Day Initiated)
Days to VOD
Resolution
Status Days at
Follow-up
or Death
Yes* Supportive care (20) Not resolved Dead; PD 101
Yes* HD steroids (31) 8 Alive 2268
Yes* HD steroids (12) 8 Dead;
chronic
GVHD
421
Yes* HD steroids (11) 6 Alive 827
Yes*,y HD steroids (19)
Deﬁbrotide (22)
69 Alive 490
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Severe VOD with MOF is a serious, life-threatening
complication of HSCT that requires prompt diagnosis and
intervention to improve clinical outcomes. It can be chal-
lenging to accurately identify VOD based on currently used
diagnostic criteria. In our retrospective series, we demon-
strate that hyperbilirubinemia may be absent even in the
presence of advancedVOD. Thepatients presented in this case
series had severe VOD meeting all other diagnostic criteria
aside from hyperbilirubinemia and also had radiologically
documented reversal of portal venous ﬂow, often believed to
be a lateﬁnding in the disease process [4,5]. Additionally, they
also had evidence of ongoing hepatic synthetic dysfunction,
as shown by abnormal coagulation panels, and MOF attrib-
uted to VOD. Although no patient had hyperbilirubinemia at
diagnosis, 3 of 5 patients developed subsequent signiﬁcant
elevation of bilirubin 1 to 11 days after diagnosis.
The literature suggests that outcomes of signiﬁcant VOD,
especially in those with MOF, have been quite dismal, with
mortality of 50% to 100% depending on deﬁnitions of severity
[1]. However, there are indications that VOD outcomes are
improved with early recognition and intervention [6,7].
Initiation of VOD directed therapy in our cohort of patients
preceded the development of hyperbilirubinemia. Despite
signiﬁcant disease with MOF, our cohort did well with
respect to their VOD, with complete resolution of organ
injury in 4 of 5 patients. One patient showed an improve-
ment in VOD-related symptoms at time of death from un-
derlying disease relapse.
Reversal of ﬂow preceding hyperbilirubinemia was pre-
viously reported in 1 patient. Matsumoto et al. [8] described
the resolution of VOD in 1 case where reversal of portal ﬂow
conﬁrmed by ultrasound preceded the development of
hyperbilirubinemia. Our observations suggest that clinically
signiﬁcant VOD without hyperbilirubinemia may be more
common than previously suspected. Finally, these ﬁndings
also suggest that the initiation of early therapeutic interven-
tion in the absence of hyperbilirubinemia may have a signif-
icant impact on VOD outcomes. Occurrence of VOD in theabsence of elevated bilirubin may limit patients’ ability to
receive VOD directed therapy available only by clinical trial,
such as deﬁbrotide, because of inability or delay in meeting
the typical eligibility criterion of bilirubinmore than 2mg/dL.
We conclude that a high index of suspicion for VOD
should be maintained in HSCT patients despite lack of bili-
rubin elevation in the presence of other diagnostic criteria
such as hepatomegaly, abdominal pain, ascites, or weight
gain. Ultrasound evaluation in these patients may lead to
earlier diagnosis, therapeutic interventions, and improved
overall outcomes.
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